This year, for the first time ever, ASCO agreed to let CNBC broadcast live from inside McCormick Place. It took years of reasoning, pleading, nagging and complaining to get inside. But finally, ASCO consented. In the past, the scientific organization has tried to keep more than an arm's distance from the financial media.   Read More

Here are some of the video clips I've done today on ASCO (American Society of Clinical Oncology) conference in Chicago. It's the world's biggest cancer conference and Wall Street's most keenly-watched medical meeting.   Read More

Next week could be the biggest week for oil and other commodities in years, says Guy Adami. What's the "Word on the Street?"   Read More

The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).   Read More

First, in the front section, Pfizer is launching a new offensive (or maybe it's defensive?) campaign on the embattled anti-smoking drug Chantix. In a full-page message signed by the company's Chief Medical Officer, Pfizer says, among other things that it's "committed to patient safety (and) furthering our knowledge of Chantix."    Read More

With the ASCO conference beginning Friday new cancer drugs are likely to grab headlines. How should you trade ahead of biotech’s biggest weekend?   Read More

Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?   Read More

This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.    Read More

The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"   Read More

It's not Carl Icahn. Earlier this month I blogged about a mysterious institutional investor taking a big stake in the ever-popular biotech Dendreon. DNDN's CFO was quoted as saying the secret admirer was familiar with biotech leading some to speculate it might be the billionaire activist investor who has taken stakes in Biogen-Idec, MedImmune and ImClone, just to name a few.   Read More